论文部分内容阅读
目的探讨全数字化钼靶对不可扪及乳腺BI-RADS4病变的微创活组织检查的临床价值。方法回顾性分析2010年11月至2013年11月在本院对不可扪及乳腺BI-RADS4病变接受全数字化钼靶的微创活组织检查的51例(55处病灶,其中4例为双侧),55处病变的临床、影像及病理资料。微创活检组织接受小焦点放大技术检测确认活检可靠。结果全组55处病灶钼靶表现为结节7例,局灶性致密1例,结构扭曲1例,无定型钙化46例,全部在全数字化钼靶定位下活检,全部被准确活检,51例(55处病灶)中,恶性病变14处,其中导管原位癌6处,浸润性导管癌8处,总体恶性率25.5%;良性病变41处,其中导管内乳头状瘤1处,纤维瘤2处,炎症1处,硬化性腺病37处,占74.5%。结论不可扪及乳腺BI-RADS4病变患者经钼靶定位下活检是一种微创、简便、实用的方法,易于推广。
Objective To investigate the clinical value of fully digital molybdenum target in the minimally invasive biopsy of intractable and breast BI-RADS4 lesions. Methods We retrospectively analyzed 51 patients (55 lesions, 4 of whom were bilateral) who underwent minimally invasive biopsy of a fully digital molybdenum target for intractable and breast BI-RADS4 lesions from November 2010 to November 2013 in our hospital. ), Clinical, imaging and pathological data of 55 lesions. The minimally-invasive biopsy tissue undergoes a small focus magnification technique to confirm the biopsy is reliable. Results The molybdenum target of the entire group consisted of 7 nodules, 1 case of focal denseness, 1 case of structural distortion, and 46 cases of amorphous calcification. All of them were biopsied under a fully digital molybdenum target, and all of them were accurately biopsied. In the 55 lesions, there were 14 malignant lesions, including 6 in situ ductal carcinomas and 8 invasive ductal carcinomas. The overall malignancy rate was 25.5%; 41 benign lesions, including one intraductal papilloma, fibroma 2 There were 1 inflammation and 37 sclerosing adenosis, accounting for 74.5%. Conclusion The biopsy of molybdenum-targeted lesions in patients with intractability and breast BI-RADS4 lesions is a minimally invasive, simple and practical method, which is easy to promote.